These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20031483)

  • 1. Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy.
    Cheung WI; Chan HL; Leung VK; Tse CH; Fung K; Lin SY; Wong A; Wong VW; Chau TN
    J Clin Virol; 2010 Feb; 47(2):193-5. PubMed ID: 20031483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays.
    Veropalumbo E; Marrone A; Vallefuoco L; Perruolo G; Orlando R; Scordino F; Tosone G; Zampino R; Trani B; Genovese A; Spadaro G; D'Orio C; Portella G
    Intervirology; 2010; 53(3):183-7. PubMed ID: 20197685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
    J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab.
    Miyagawa M; Minami M; Fujii K; Sendo R; Mori K; Shimizu D; Nakajima T; Yasui K; Itoh Y; Taniwaki M; Okanoue T; Yoshikawa T
    J Med Virol; 2008 Dec; 80(12):2069-78. PubMed ID: 19040281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
    Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
    J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection.
    Kao JH; Chen PJ; Lai MY; Chen DS
    J Med Virol; 2002 Oct; 68(2):216-20. PubMed ID: 12210410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
    Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
    J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient.
    Awerkiew S; Däumer M; Reiser M; Wend UC; Pfister H; Kaiser R; Willems WR; Gerlich WH
    J Clin Virol; 2007 Jan; 38(1):83-6. PubMed ID: 17134939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus genotypes and hepatitis B surface antigen mutations in family contacts of hepatitis B virus infected patients with occult hepatitis B virus infection.
    Kumar GT; Kazim SN; Kumar M; Hissar S; Chauhan R; Basir SF; Sarin SK
    J Gastroenterol Hepatol; 2009 Apr; 24(4):588-98. PubMed ID: 19207682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of a premature stop codon in the surface gene of hepatitis B virus from an HBsAg and antiHBc negative blood donor.
    Datta S; Banerjee A; Chandra PK; Chakraborty S; Basu SK; Chakravarty R
    J Clin Virol; 2007 Nov; 40(3):255-8. PubMed ID: 17869170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occult hepatitis B virus infection: implications in transfusion.
    Allain JP
    Vox Sang; 2004 Feb; 86(2):83-91. PubMed ID: 15023176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and serological evaluation of surface antigen negative hepatitis B virus infection in blood donors from Venezuela.
    Gutiérrez C; Devesa M; Loureiro CL; León G; Liprandi F; Pujol FH
    J Med Virol; 2004 Jun; 73(2):200-7. PubMed ID: 15122793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial analysis of hepatitis B virus DNA from hepatocellular carcinoma showing negative hepatitis B virus surface antigen: an analysis of two Japanese cases.
    Shiota G; Oyama K; Udagawa A; Nomi T; Tanaka K; Tsutsumi A; Noguchi N; Okano J; Kishimoto Y; Kanbe T; Kishimoto H; Kawasaki H
    Hepatogastroenterology; 2009; 56(94-95):1516-20. PubMed ID: 19950820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype, phylogenetic analysis, and transmission pattern of occult hepatitis B virus (HBV) infection in families of asymptomatic HBsAg carriers.
    Datta S; Banerjee A; Chandra PK; Chowdhury A; Chakravarty R
    J Med Virol; 2006 Jan; 78(1):53-9. PubMed ID: 16299727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage.
    Hsieh YH; Su IJ; Wang HC; Chang WW; Lei HY; Lai MD; Chang WT; Huang W
    Carcinogenesis; 2004 Oct; 25(10):2023-32. PubMed ID: 15180947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
    Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
    J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occult hepatitis B virus infection.
    Allain JP
    Transfus Clin Biol; 2004 Feb; 11(1):18-25. PubMed ID: 14980545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.
    Hui CK; Cheung WW; Zhang HY; Au WY; Yueng YH; Leung AY; Leung N; Luk JM; Lie AK; Kwong YL; Liang R; Lau GK
    Gastroenterology; 2006 Jul; 131(1):59-68. PubMed ID: 16831590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays.
    La'ulu SL; Roberts WL
    Am J Clin Pathol; 2006 May; 125(5):748-51. PubMed ID: 16707377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.